GSK and Medicago’s Plant-based Covifenz Vaccine Approved in Canada
Health Canada has approved GlaxoSmithKline and Medicago's Covifenz COVID-19 vaccine, a plant-based virus-like particles, recombinant, adjuvanted vaccine, for adults age 18-64.
Tag: GSK Medicago Covifenz
All
Latest
GSK and Medicago’s Plant-based Covifenz Vaccine Approved in Canada
Health Canada has approved GlaxoSmithKline and Medicago’s Covifenz COVID-19 vaccine, a plant-based virus-like particles, recombinant, adjuvanted vaccine, for adults age 18-64.
Read More